Pronova BioPharma in brief

Pronova BioPharma is a global leader in the research, development and manufacture of marine originated omega-3 derived pharmaceutical products. 

Our first commercialised product is branded as Omacor® globally and Lovaza™ in the USA. Omacor/Lovaza is the only EU and FDA-approved omega-3 derived prescription drug.

Omacor/Lovaza is both efficacious and safe and is approved in the USA and in Europe for the treatment of elevated levels of triglycerides in humans, a condition known as hypertriglyceridemia, or HTG. It is also approved in Europe for secondary prevention of post-myocardial infarction, or Post-MI, the period following the survival of a heart attack.

Omacor/Lovaza is produced through a documented, unique and complex process. It is sold and distributed in more than 40 countries around the world by our strong, regional business partners. Our main markets include the USA, the UK, Italy, Germany, France, Spain and Japan, known as the seven major global pharmaceutical markets. The demand for Omacor/Lovaza has grown significantly during the last years and is expected to continue growing.

Our extensive research and development activity includes a solid pipeline of collaborative projects to develop the use of the company’s active pharmaceutical ingredient further through clinical trials as a monotherapy for additional indications such as atrial fibrillation, heart failure and primary prevention in type II diabetes. These projects are all in phase III clinical development, except the GISSI heart failure trial, which has recently completed Phase III, showing that Omacor/Lovaza reduces mortality and morbidity in patients with chronic heart failure.

Together with our partners, we are also involved in combination therapy projects for HTG and mixed dyslipidemia, as well as a new formulation capsule. Moreover, we are involved in a number of early stages of discovery projects and preclinical studies for next generation omega-3 derived products.

Pronova BioPharma is based in Norway and Denmark, with a production plant located in Sandefjord, south of Oslo, a second production plant under construction in Kalunborg, Denmark, and headquarter in Lysaker, just outside Oslo. The group comprises about 250 full time employees. Total revenues in 2007 were NOK 1 014.4 million, and the EBITDA was NOK 503.0 million.

Pronova BioPharma is listed on Oslo Børs and has the private equity fund Herkules I as its largest shareholder.
The Pronova BioPharma group comprises the listed parent company, Pronova BioPharma ASA, and the two operating units Pronova BioPharma Norge AS in Norway and Pronova BioPharma Danmark A/S in Denmark.